Menu

Does Pot Cause Mental Decline?

A new study casts doubt on previous research linking early marijuana use to drops in IQ.

Jan 15, 2013
Kate Yandell

WIKIMEDIA, BOGDAN GIUSCAA study claiming that pot use in youth has long-term cognitive effects is being challenged. The original study, published last year in the Proceedings of the National Academy of Sciences (PNAS), found that smoking marijuana as a teenager may be associated with IQ declines by middle age. The new study, published in the same journal on Monday (January 14), said that IQ declines were likely a product of socioeconomic status, Nature reported.

“Although it would be too strong to say that the results have been discredited, the methodology is flawed and the causal inference drawn from the results premature,” Ole Røgeberg, the sole author of the new study and an economist at The Ragnar Frisch Centre for Economic Research in Oslo, wrote in the paper.

Both papers used data from the Dunedin Study, which followed more than 1,000 New Zealanders from birth to until age 38 and interviewed them periodically about cannabis use starting at age 18. Previous analyses of the Dunedin Study showed that starting to use marijuana young and becoming dependent on it were both associated with low socioeconomic status. Røgeberg said that low socioeconomic status, which may come with lower educational attainment and less challenging work, is associated with IQ declines.

But Madeline Meier, a psychologist at Duke University and author of the original PNAS study, said that her study controlled for socioeconomic status and found that, among participants who did not use marijuana heavily in their youths, IQ remained the same throughout the study regardless of socioeconomic status.

Other research has shown that in the short-term, marijuana use is related to reversible problems with memory and focus.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.